BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramalho R, Pereira AC, Vicente F, Pereira P. Docosahexaenoic acid supplementation for children with attention deficit hyperactivity disorder: A comprehensive review of the evidence. Clin Nutr ESPEN 2018;25:1-7. [PMID: 29779801 DOI: 10.1016/j.clnesp.2018.03.126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang GY, Wu T, Huang SY, Huang BX, Wang HL, Lan QY, Li CL, Zhu HL, Fang AP. No effect of 6-month supplementation with 300 mg/d docosahexaenoic acid on executive functions among healthy school-aged children: a randomized, double-blind, placebo-controlled trial. Eur J Nutr 2021;60:1985-97. [PMID: 32979077 DOI: 10.1007/s00394-020-02388-w] [Reference Citation Analysis]
2 Mallick R, Basak S, Duttaroy AK. Docosahexaenoic acid,22:6n-3: Its roles in the structure and function of the brain. Int J Dev Neurosci 2019;79:21-31. [PMID: 31629800 DOI: 10.1016/j.ijdevneu.2019.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
3 Rodríguez C, García T, Areces D, Fernández E, García-Noriega M, Domingo JC. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Neuropsychiatr Dis Treat 2019;15:1193-209. [PMID: 31190827 DOI: 10.2147/NDT.S206020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Fuentes-Albero M, Martínez-Martínez MI, Cauli O. Omega-3 Long-Chain Polyunsaturated Fatty Acids Intake in Children with Attention Deficit and Hyperactivity Disorder. Brain Sci 2019;9:E120. [PMID: 31126106 DOI: 10.3390/brainsci9050120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
5 Reimers A, Ljung H. The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders. Ther Adv Psychopharmacol 2019;9:2045125319858901. [PMID: 31258889 DOI: 10.1177/2045125319858901] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]